Healthcare

Interactive Strength Inc. (Nasdaq:TRNR) Updates FAQ’s About Increased Guidance to $80M Pro Forma Revenue, Sportstech and TRNR’s $50M Digital Asset Treasury

AUSTIN, TX / ACCESS Newswire / September 11, 2025 / Interactive Strength Inc. (NASDAQ:TRNR) ("TRNR" or the "Company"), maker of…

4 months ago

MentalHealth.com Responds to WHO’s Call: Scaling Global Solutions for Mental Health

One Billion People Living With Mental Health Conditions ATLANTA, GA / ACCESS Newswire / September 11, 2025 / The World…

4 months ago

MentalHealth.com Responds to WHO’s Call: Scaling Global Solutions for Mental Health

One Billion People Living With Mental Health Conditions ATLANTA, GA / ACCESS Newswire / September 11, 2025 / The World…

4 months ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development,…

4 months ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025…

4 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a…

4 months ago

Avel eCare’s Dr. Kelly Rhone to Speak on Rural Health Panel at ATA Annual Conference

SIOUX FALLS, SD / ACCESS Newswire / September 11, 2025 / Avel eCare today announced that Dr. Kelly Rhone, Chief…

4 months ago

Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring

Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical…

4 months ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3…

4 months ago

Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold

MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today…

4 months ago